Related Experiment Video
Updated: Jun 20, 2026
10:02
Standardized SDS-PAGE Workflow for Personalized Protein Corona Profiling in Early Cancer Detection
Published on: December 19, 2025
European Partnership for Personalised Medicine (EP PerMed).
Casopis Lekaru Ceskych
|June 18, 2026
Summary
Personalised medicine tailors healthcare to individual needs. The European Partnership for Personalised Medicine (EP PerMed) coordinates research and implementation across Europe, including the Czech Republic.
Area of Science:
- Healthcare innovation
- Medical research
- Public health policy
Background:
- Personalised medicine is advancing healthcare by tailoring prevention, diagnosis, and treatment to individual patient characteristics.
- The European Partnership for Personalised Medicine (EP PerMed) was established to coordinate personalised medicine efforts across European Union Member States.
- The Czech Republic's involvement is facilitated by the Czech Health Research Council (AZV ČR).
Purpose of the Study:
- To provide a comprehensive overview of the European Partnership for Personalised Medicine (EP PerMed).
- To highlight the objectives, programmes, and challenges of EP PerMed.
- To focus on the relevance of EP PerMed for clinicians and researchers, and the participation of the Czech Republic.
Main Methods:
- Literature review and analysis of EP PerMed initiatives.
- Examination of the role of national coordinating bodies like AZV ČR.
- Discussion of European and Czech contexts for personalised medicine.
Main Results:
- EP PerMed aims to coordinate research, innovation, and implementation of personalised medicine.
- The Czech Health Research Council (AZV ČR) plays a crucial role in facilitating Czech participation in EP PerMed joint calls.
- The article outlines the benefits and future perspectives of personalised medicine in Europe and the Czech Republic.
Conclusions:
- EP PerMed is a key initiative for advancing personalised medicine in Europe.
- Effective national coordination is vital for successful participation in international research partnerships.
- Personalised medicine holds significant promise for the future of healthcare in both European and Czech contexts.
Keywords:
AZV ČREP PerMedEuropean partnershipsclinical researchhealth researchpersonalised medicineprecision medicineMore Related Videos
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:19Clinical Applications of Epidermal Stem Cells
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own EpiSCs...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...